Hims & Hers Health (HIMS) Tops Q2 EPS by 2c, Revenue Misses, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
BTIG Reiterates Buy Rating on Hims and Hers (HIMS), PT $85
August 5, 2025 9:32 AM EDTBTIG analyst David Larsen reiterated a Buy rating and $85.00 price target on Hims and Hers (NYSE: HIMS).
The analyst comments " On Monday, AMC, HIMS reported 2Q:25 results. Revenue of $544.8M +73% y/y was behind BTIG / consensus of $560.9M / $552M though adjusted EBITDA of $82.2M was well ahead of BTIG / consensus of $80.4M / $73M. Excluding several increases in costs related to hiring new talent, EBITDA would have been closer to ~$90M. Relative to our model, the... More
Hims and Hers (HIMS) PT Raised to $43 at Leerink Partners
August 5, 2025 6:36 AM EDTLeerink Partners analyst Michael Cherny raised the price target on Hims and Hers (NYSE: HIMS) to $43.00 (from $42.00) while maintaining a Market Perform rating.
The analyst comments "Bottom Line: HIMS appears to be in somewhat of a transitory stage, with the companys first revenue miss driven by both the sequential (expected) decline in GLP-1 revenue and the sequential (unexpected) decline in core revenue outside of GLP-1s. We... More
